Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about Vaxcyte, Inc.
Vaxcyte, Inc. News
Vaxcyte, Inc. Quantitative Score
About Vaxcyte, Inc.
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company also develops VAX-XP to protect against emerging strains and address antibiotic resistance; VAX-A1, a conjugate vaccine candidate designed to treat Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.
Vaxcyte, Inc. Earnings & Revenue
What’s This Company Really Worth? Find Out Instantly.
Warren Buffett’s go-to valuation method is Discounted Cash Flow (DCF). Our tool makes it effortless — no spreadsheets, just answers in a few clicks.
Vaxcyte, Inc. Financials
Table Compare
Compare PCVX metrics with: | |||
|---|---|---|---|
Earnings & Growth | PCVX | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | PCVX | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | PCVX | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | PCVX | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
Vaxcyte, Inc. Income
Vaxcyte, Inc. Balance Sheet
Vaxcyte, Inc. Cash Flow
Vaxcyte, Inc. Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Neutral |
| Return on Equity | Strong Sell |
| Return on Assets | Strong Sell |
| Debt/Equity Ratio | Neutral |
| Price/Earnings Ratio | Strong Sell |
| Price/Book Ratio | Neutral |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Historical Market Cap
Shares Outstanding
Vaxcyte, Inc. Executives
| Name | Role |
|---|---|
| Mr. Grant E. Pickering M.B.A. | Co-Founder, Chief Executive Officer & Director |
| Mr. Andrew L. Guggenhime M.B.A. | President & Chief Financial Officer |
| Mr. Mikhail Eydelman J.D. | Senior Vice President, General Counsel, Chief Compliance Officer & Corporate Secretary |
| Mr. Paul W. Sauer M.B.A. | Senior Vice President of Process Development & Manufacturing |
| Mr. James Wassil M.B.A., M.S. | Executive Vice President & Chief Operating Officer |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Mr. Grant E. Pickering M.B.A. | Co-Founder, Chief Executive Officer & Director | Male | 1968 | 1.4M |
| Mr. Andrew L. Guggenhime M.B.A. | President & Chief Financial Officer | Male | 1968 | 987.8K |
| Mr. Mikhail Eydelman J.D. | Senior Vice President, General Counsel, Chief Compliance Officer & Corporate Secretary | Male | 1981 | 813.77K |
| Mr. Paul W. Sauer M.B.A. | Senior Vice President of Process Development & Manufacturing | Male | 1962 | 608.96K |
| Mr. James Wassil M.B.A., M.S. | Executive Vice President & Chief Operating Officer | Male | 1969 | 564.81K |
Vaxcyte, Inc. Insider Trades
| Date | 1 May |
| Name | BRANDICOURT OLIVIER |
| Role | Director |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 40113 |
| Date | 1 May |
| Name | BRANDICOURT OLIVIER |
| Role | Director |
| Transaction | Disposed |
| Type | |
| Shares | 0 |
| Date | 17 Apr |
| Name | Dhaliwal Harpreet S. |
| Role | Chief Technical Ops Officer |
| Transaction | Disposed |
| Type | |
| Shares | 0 |
| Date | 17 Apr |
| Name | Dhaliwal Harpreet S. |
| Role | Chief Technical Ops Officer |
| Transaction | Disposed |
| Type | |
| Shares | 96010 |
| Date | 17 Apr |
| Name | Dhaliwal Harpreet S. |
| Role | Chief Technical Ops Officer |
| Transaction | Disposed |
| Type | |
| Shares | 45000 |
| Date | Name | Role | Transaction | Type | Shares |
|---|---|---|---|---|---|
| 1 May | BRANDICOURT OLIVIER | Director | Acquired | A-Award | 40113 |
| 1 May | BRANDICOURT OLIVIER | Director | Disposed | 0 | |
| 17 Apr | Dhaliwal Harpreet S. | Chief Technical Ops Officer | Disposed | 0 | |
| 17 Apr | Dhaliwal Harpreet S. | Chief Technical Ops Officer | Disposed | 96010 | |
| 17 Apr | Dhaliwal Harpreet S. | Chief Technical Ops Officer | Disposed | 45000 |